Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CC-95775 · 1 trial · 1 indication
is defined as any toxicities occurring within the DLT assessment unless the event can clearly be determined to be unrelated to CC-95775.
dose level that could be given such that the estimated DLT probability is closest to 25%.
The dose that is higher than MTD
Number of participants with adverse event. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study
| Arm | Type | Description |
|---|---|---|
| CC-95775 | EXPERIMENTAL | Escalating dose finding part A of study and extension Part B of the study. In Part A, subjects will be treated with oral capsules of CC-95775 with a schedule of 4d on/ 24d off (Q4W) and a starting dose of 100 mg/day on a 28-day cycle. Dose increments between cohorts will not exceed 100% of the dose in previous cohort. Patients in Part B will be treated with a schedule of 4d on/24d off (Q4W) at the Maximum tolerated dose (MTD) established from Part A. |
| Name | Type | Description |
|---|---|---|
| CC-95775 | DRUG | CC-95775 |
Inclusion Criteria: Subjects must satisfy the criteria below to be enrolled in dose escalation (Part A) and in dose expansion (Part B) of this study. 1. Men and women ≥ 18 years of age, at the time of signing the ICF. 2. Subject must understand and voluntarily sign an ICF prior to any study-specif...
CC-95775 is an investigational small molecule developed by Bristol-Myers Squibb Company (ticker: BMY) for the treatment of non-Hodgkin lymphoma. It is designed to target BCMA. The compound has been studied in a Phase 1 clinical trial in adults with advanced solid tumors and relapsed or refractory non-Hodgkin lymphoma.
CC-95775 is being studied for relapsed or refractory non-Hodgkin lymphoma. It is an investigational agent and is not approved for any indication. The Phase 1 trial that evaluated CC-95775 enrolled adults with advanced solid tumors and relapsed or refractory non-Hodgkin lymphoma.
CC-95775 targets BCMA, also known as B-cell maturation antigen. BCMA is a molecular target of interest in B-cell malignancies, including non-Hodgkin lymphoma. CC-95775 is a small molecule directed at this target and was evaluated in a Phase 1 study in advanced solid tumors and relapsed or refractory non-Hodgkin lymphoma.
CC-95775 is developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. Bristol-Myers Squibb sponsored the Phase 1 clinical trial of CC-95775 in patients with advanced solid tumors and relapsed or refractory non-Hodgkin lymphoma.
CC-95775 is in Phase 1 development. It is an investigational drug and has not been approved by the FDA for any indication. The single Phase 1 trial of CC-95775 has been completed, and no trials of CC-95775 are currently active.
CC-95775 has been evaluated in one Phase 1 clinical trial, NCT04089527, titled a study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CC-95775 in subjects with advanced solid tumors and relapsed or refractory non-Hodgkin lymphoma. The trial enrolled 24 participants across France and Spain and is completed.